Talking Points

Episode 101: PARTNER 2A: 5-Year Outcomes

Informações:

Sinopsis

C. Michael Gibson and Vinod Thourani discuss 5-year outcomes in this randomized trial of TAVR vs SAVR in intermediate-risk patients.